ArticleCase reports in urology2026
Clear Cell Renal Cell Carcinoma: Rare and Atypical Metastatic Localizations-A Case Series.
Article in Case reports in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clear Cell Renal Cell Carcinoma: Rare and Atypical Metastatic Localizations-A Case Series.Case reports in urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of kidney cancer, characterized by its high degree of vascularity and metastatic potential. Although common metastatic sites include the lungs, lymph nodes, bones, liver, adrenal glands, and brain, rare localizations, such as those observed in the pancreas, gallbladder, thyroid gland, and nasal cavities, pose significant diagnostic and therapeutic challenges. Case presentation: The following report details four cases of ccRCC with atypical metastatic localizations: A nasal metastasis in one patient, a thyroid metastasis in one patient, a gallbladder metastasis in one patient, and pancreatic localizations in all four patients. These metastases, frequently asymptomatic, contributed to delays in diagnosis. The therapeutic management of these cases was individualized, incorporating surveillance, surgical intervention, radiotherapy, or immunotherapy, depending on the patient's clinical profile and the progression of the lesions. Conclusion: This series illustrates the diversity of metastatic presentations of ccRCC and highlights the importance of prolonged, personalized follow-up after nephrectomy. A multidisciplinary approach remains essential for the timely detection and optimal management of rare metastatic sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.